FORE Biotherapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA--(BUSINESS WIRE)-- FORE Biotherapeutics today announced that the Company will participate at the following investor conferences:

• Stifel 2026 Virtual Targeted Oncology Forum. The Company will attend on Tuesday, May 19, and will participate in a fireside chat at 12:30 p.m. ET.

• Jefferies 2026 Global Healthcare Conference. The Company will attend and participate in one-on-one meetings on Tuesday, June 2.

Management will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.

About FORE Biotherapeutics

Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1st and 2nd generation BRAF inhibitors. For more information, please visit www.fore.bio or follow us on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260512052944/en/

Investors and Media:

Argot Partners
212.600.1902 | [email protected]

Source: FORE Biotherapeutics

You May Also Be Interested In

• Norton Manx R Earns Landmark International Design Excellence Award for Reimagining the Superbike
• How Minecraft's Creator Economy Keeps Growing After 17 Years
• 2026 AI Creator Festival Concludes in Bali: Wan3.0 and Global Creators Explore the New Frontier of AI Video Generation